A Prospective Observational Study of Osimertinib for Chemo-Naive Elderly Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer.

Satoshi IgawaMasashi KasajimaTaihei OnoTakahiro OzawaMikiko KakegawaSeiichiro KusuharaTakashi SatoYoshiro NakaharaTomoya FukuiMasanori YokobaMasaru KubotaHisashi MitsufujiJiichiro SasakiKatsuhiko Naoki

Published in: Cancer management and research (2021)

Considering the findings of this study and despite an observed discordance between PFS and TTF, osimertinib appears to be an effective and safe treatment option in elderly patients with advanced NSCLC harboring sensitive EGFR mutations. To obtain conclusive results, further studies in a larger elderly population are warranted.

Keyphrases

small cell lung cancer
epidermal growth factor receptor
advanced non small cell lung cancer
middle aged
community dwelling
tyrosine kinase
brain metastases
combination therapy
photodynamic therapy
squamous cell carcinoma
hiv infected
smoking cessation